Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways
Background. Sodium-glucose cotransporter 2 (SGLT2) and dipeptidyl peptidase-4 (DPP-4) inhibitors are glucose-lowering drugs whose anti-inflammatory properties have recently become useful in tackling metabolic syndromes in chronic inflammatory diseases, including diabetes and obesity. We investigated...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2021/9944880 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560709245861888 |
|---|---|
| author | Nami Lee Yu Jung Heo Sung-E Choi Ja Young Jeon Seung Jin Han Dae Jung Kim Yup Kang Kwan Woo Lee Hae Jin Kim |
| author_facet | Nami Lee Yu Jung Heo Sung-E Choi Ja Young Jeon Seung Jin Han Dae Jung Kim Yup Kang Kwan Woo Lee Hae Jin Kim |
| author_sort | Nami Lee |
| collection | DOAJ |
| description | Background. Sodium-glucose cotransporter 2 (SGLT2) and dipeptidyl peptidase-4 (DPP-4) inhibitors are glucose-lowering drugs whose anti-inflammatory properties have recently become useful in tackling metabolic syndromes in chronic inflammatory diseases, including diabetes and obesity. We investigated whether empagliflozin (SGLT2 inhibitor) and gemigliptin (DPP-4 inhibitor) improve inflammatory responses in macrophages, identified signalling pathways responsible for these effects, and studied whether the effects can be augmented with dual empagliflozin and gemigliptin therapy. Methods. RAW 264.7 macrophages were first stimulated with lipopolysaccharide (LPS), then cotreated with empagliflozin, gemigliptin, or empagliflozin plus gemigliptin. We conducted quantitative RT-PCR (qRT-PCR) to determine the most effective anti-inflammatory doses without cytotoxicity. We performed ELISA and qRT-PCR for inflammatory cytokines and chemokines and flow cytometry for CD80, the M1 macrophage surface marker, to evaluate the anti-inflammatory effects of empagliflozin and gemigliptin. NF-κB, MAPK, and JAK2/STAT signalling pathways were examined via Western blotting to elucidate the molecular mechanisms of anti-inflammation. Results. LPS-stimulated CD80+ M1 macrophages were suppressed by coincubation with empagliflozin, gemigliptin, and empagliflozin plus gemigliptin, respectively. Empagliflozin and gemigliptin (individually and combined) inhibited prostaglandin E2 (PGE2) release and COX-2, iNOS gene expression in LPS-stimulated RAW 264.7 macrophages. These three treatments also attenuated the secretion and mRNA expression of proinflammatory cytokines, such as TNF-α, IL-1β, IL-6, and IFN-γ, and proinflammatory chemokines, such as CCL3, CCL4, CCL5, and CXCL10. All of them blocked NF-κB, JNK, and STAT1/3 phosphorylation through IKKα/β, MKK4/7, and JAK2 signalling. Conclusions. Our study demonstrated the anti-inflammatory effects of empagliflozin and gemigliptin via IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 pathway downregulation in macrophages. In all cases, combined empagliflozin and gemigliptin treatment showed greater anti-inflammatory properties. |
| format | Article |
| id | doaj-art-f80b1e9f48bd4005bb8827e38d0b6477 |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-f80b1e9f48bd4005bb8827e38d0b64772025-02-03T01:26:58ZengWileyJournal of Immunology Research2314-88612314-71562021-01-01202110.1155/2021/99448809944880Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling PathwaysNami Lee0Yu Jung Heo1Sung-E Choi2Ja Young Jeon3Seung Jin Han4Dae Jung Kim5Yup Kang6Kwan Woo Lee7Hae Jin Kim8Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Republic of KoreaDepartment of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Republic of KoreaDepartment of Physiology, Ajou University School of medicine, Suwon, Republic of KoreaDepartment of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Republic of KoreaDepartment of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Republic of KoreaDepartment of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Republic of KoreaDepartment of Physiology, Ajou University School of medicine, Suwon, Republic of KoreaDepartment of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Republic of KoreaDepartment of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Republic of KoreaBackground. Sodium-glucose cotransporter 2 (SGLT2) and dipeptidyl peptidase-4 (DPP-4) inhibitors are glucose-lowering drugs whose anti-inflammatory properties have recently become useful in tackling metabolic syndromes in chronic inflammatory diseases, including diabetes and obesity. We investigated whether empagliflozin (SGLT2 inhibitor) and gemigliptin (DPP-4 inhibitor) improve inflammatory responses in macrophages, identified signalling pathways responsible for these effects, and studied whether the effects can be augmented with dual empagliflozin and gemigliptin therapy. Methods. RAW 264.7 macrophages were first stimulated with lipopolysaccharide (LPS), then cotreated with empagliflozin, gemigliptin, or empagliflozin plus gemigliptin. We conducted quantitative RT-PCR (qRT-PCR) to determine the most effective anti-inflammatory doses without cytotoxicity. We performed ELISA and qRT-PCR for inflammatory cytokines and chemokines and flow cytometry for CD80, the M1 macrophage surface marker, to evaluate the anti-inflammatory effects of empagliflozin and gemigliptin. NF-κB, MAPK, and JAK2/STAT signalling pathways were examined via Western blotting to elucidate the molecular mechanisms of anti-inflammation. Results. LPS-stimulated CD80+ M1 macrophages were suppressed by coincubation with empagliflozin, gemigliptin, and empagliflozin plus gemigliptin, respectively. Empagliflozin and gemigliptin (individually and combined) inhibited prostaglandin E2 (PGE2) release and COX-2, iNOS gene expression in LPS-stimulated RAW 264.7 macrophages. These three treatments also attenuated the secretion and mRNA expression of proinflammatory cytokines, such as TNF-α, IL-1β, IL-6, and IFN-γ, and proinflammatory chemokines, such as CCL3, CCL4, CCL5, and CXCL10. All of them blocked NF-κB, JNK, and STAT1/3 phosphorylation through IKKα/β, MKK4/7, and JAK2 signalling. Conclusions. Our study demonstrated the anti-inflammatory effects of empagliflozin and gemigliptin via IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 pathway downregulation in macrophages. In all cases, combined empagliflozin and gemigliptin treatment showed greater anti-inflammatory properties.http://dx.doi.org/10.1155/2021/9944880 |
| spellingShingle | Nami Lee Yu Jung Heo Sung-E Choi Ja Young Jeon Seung Jin Han Dae Jung Kim Yup Kang Kwan Woo Lee Hae Jin Kim Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways Journal of Immunology Research |
| title | Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways |
| title_full | Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways |
| title_fullStr | Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways |
| title_full_unstemmed | Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways |
| title_short | Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways |
| title_sort | anti inflammatory effects of empagliflozin and gemigliptin on lps stimulated macrophage via the ikk nf κb mkk7 jnk and jak2 stat1 signalling pathways |
| url | http://dx.doi.org/10.1155/2021/9944880 |
| work_keys_str_mv | AT namilee antiinflammatoryeffectsofempagliflozinandgemigliptinonlpsstimulatedmacrophageviatheikknfkbmkk7jnkandjak2stat1signallingpathways AT yujungheo antiinflammatoryeffectsofempagliflozinandgemigliptinonlpsstimulatedmacrophageviatheikknfkbmkk7jnkandjak2stat1signallingpathways AT sungechoi antiinflammatoryeffectsofempagliflozinandgemigliptinonlpsstimulatedmacrophageviatheikknfkbmkk7jnkandjak2stat1signallingpathways AT jayoungjeon antiinflammatoryeffectsofempagliflozinandgemigliptinonlpsstimulatedmacrophageviatheikknfkbmkk7jnkandjak2stat1signallingpathways AT seungjinhan antiinflammatoryeffectsofempagliflozinandgemigliptinonlpsstimulatedmacrophageviatheikknfkbmkk7jnkandjak2stat1signallingpathways AT daejungkim antiinflammatoryeffectsofempagliflozinandgemigliptinonlpsstimulatedmacrophageviatheikknfkbmkk7jnkandjak2stat1signallingpathways AT yupkang antiinflammatoryeffectsofempagliflozinandgemigliptinonlpsstimulatedmacrophageviatheikknfkbmkk7jnkandjak2stat1signallingpathways AT kwanwoolee antiinflammatoryeffectsofempagliflozinandgemigliptinonlpsstimulatedmacrophageviatheikknfkbmkk7jnkandjak2stat1signallingpathways AT haejinkim antiinflammatoryeffectsofempagliflozinandgemigliptinonlpsstimulatedmacrophageviatheikknfkbmkk7jnkandjak2stat1signallingpathways |